WFDC2 and neoplasm: Consequently, over the next 6 months, the patient received six cycles of combined paclitaxel/carboplatin chemotherapy, with bevacizumab added in the first and the last cycles, and her tumor markers increased (CA125 24.8 U/mL, HE4 299 pmol/L).